Clinical Trials Browser

Phase 3 × parsaclisib × Lymphoid × Clear all

NCT04796922 2022-07-18

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04849715 2022-04-29

CITADEL-310

Phase 3 Withdrawn

Lymphoma, Mantle-Cell